HZ

Hangzhou Zhiyan Dongli Jishu Management Consulting

Asia, Zhejiang, China, Hangzhou

Description

Hangzhou Zhiyan Dongli Jishu Management Consulting is engaged in power technology consulting, investment management, etc.

Investor Profile

Hangzhou Zhiyan Dongli Jishu Management Consulting has backed more than 1 startups, with 0 new investments in the last 12 months alone. The firm has led 0 rounds, about 0% of its total and boasts 1 exits across its portfolio.

Investment Focus Highlights

  • Concentrates on Series E rounds (top funding stages).
  • Majority of deals are located in China.
  • Strong thematic focus on Biotechnology, Health Care, Pharmaceutical.

Stage Focus

  • Series E (100%)

Country Focus

  • China (100%)

Industry Focus

  • Biotechnology
  • Health Care
  • Pharmaceutical
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Hangzhou Zhiyan Dongli Jishu Management Consulting frequently co-invest with?

SC
Europe, Noord-Holland, The Netherlands, Amsterdam
Co-Investments: 1
Hudson Bay Capital Management
North America, New York, United States, New York
Co-Investments: 1
BGI Co-Win
Asia, Guangdong, China, Shenzhen
Co-Investments: 1
DNV capital
Asia, Guangdong, China, Shenzhen
Co-Investments: 1
Casdin Capital
North America, New York, United States, New York
Co-Investments: 1
Bulldog Innovation Group LLC
North America, Connecticut, United States, New Haven
Co-Investments: 1
RA Capital Management
North America, Massachusetts, United States, Boston
Co-Investments: 1
SPDB International Holdings
Asia, Hong Kong Island, Hong Kong, Hong Kong
Co-Investments: 1
LYFE Capital
Asia, Central Region, Singapore, Singapore
Co-Investments: 1
3P
North America, Missouri, United States, Saint Louis
Co-Investments: 1

What are some of recent deals done by Hangzhou Zhiyan Dongli Jishu Management Consulting?

CANbridge Pharmaceuticals

Beijing, Beijing, China

CANbridge Pharmaceuticals is a bio-pharmaceutical company accelerating development and commercialization of specialty healthcare .

BiotechnologyHealth CarePharmaceutical
Series EDec 1, 2020
Amount Raised: $43,000,000